Glycan-Based Cell Targeting To Modulate Immune Responses

Trends in Biotechnology

Volumn 35, Issue 4, 2017, Pages 334-346

  Johannssen, Timo ^a,b,c   Lepenies, Bernd ^c  

^a MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

C type lectin receptors; carbohydrates; dendritic cells; glycoengineering; immune modulation; innate immunity

Indexed keywords

CARBOHYDRATES; CELLS; CHEMICAL STABILITY; CYTOLOGY; DENDRIMERS; GLYCOPROTEINS; GLYCOSYLATION; LIPOSOMES; MAMMALS; MODULATION; NANOPARTICLES; POLYSACCHARIDES; PROTEINS; YEAST;

C-TYPE LECTINS; DENDRITIC CELLS; GLYCOENGINEERING; IMMUNE MODULATION; INNATE IMMUNITY;

IMMUNE SYSTEM;

GLYCAN; GLYCOPROTEIN; LECTIN RECEPTOR; LECTIN; POLYSACCHARIDE;

ENGINEERING; GLYCOBIOLOGY; GLYCOENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GLYCOSYLATION; METABOLISM; MOUSE; PHYSIOLOGY; PROCEDURES; PROTEIN ENGINEERING; PROTEIN PROCESSING;

ANIMALS; DRUG DELIVERY SYSTEMS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LECTINS, C-TYPE; MICE; POLYSACCHARIDES; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 85006008530     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.10.002     Document Type: Review

References (85)

1. 1 Lepenies, B., et al. Applications of synthetic carbohydrates to chemical biology. Curr. Opin. Chem. Biol. 14 (2010), 404–411.
2. 2 Hudak, J.E., Bertozzi, C.R., Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem. Biol. 21 (2014), 16–37.
3. 3 Lepenies, B., Seeberger, P.H., Simply better glycoproteins. Nat. Biotechnol. 32 (2014), 443–445.
4. 4 Wacker, M., et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298 (2002), 1790–1793.
5. 5 Anyaogu, D.C., Mortensen, U.H., Manipulating the glycosylation pathway in bacterial and lower eukaryotes for production of therapeutic proteins. Curr. Opin. Biotechnol. 36 (2015), 122–128.
6. 6 Valderrama-Rincon, J.D., et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat. Chem. Biol. 8 (2012), 434–436.
7. 7 Naegeli, A., et al. Molecular analysis of an alternative N-glycosylation machinery by functional transfer from Actinobacillus pleuropneumoniae to Escherichia coli. J. Biol. Chem. 289 (2014), 2170–2179.
8. 8 Hu, Q.Y., et al. Towards the next generation of biomedicines by site-selective conjugation. Chem. Soc. Rev. 45 (2016), 1691–1719.
9. 9 Hamilton, S.R., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (2006), 1441–1443.
10. 10 Hamilton, S.R., Zha, D., Progress in yeast glycosylation engineering. Methods Mol. Biol. 1321 (2015), 73–90.
11. 11 Halim, A., et al. Discovery of a nucleocytoplasmic O-mannose glycoproteome in yeast. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 15648–15653.
12. 12 Geisler, C., et al. An Overview and history of glyco-engineering in insect expression systems. Methods Mol. Biol. 1321 (2015), 131–152.
13. 13 Aumiller, J.J., et al. A new glycoengineered insect cell line with an inducibly mammalianized protein N-glycosylation pathway. Glycobiology 22 (2012), 417–428.
14. 14 Mabashi-Asazuma, H., et al. Modifying an insect cell N-glycan processing pathway using CRISPR-Cas technology. ACS Chem. Biol. 10 (2015), 2199–2208.
15. 15 Butler, M., Spearman, M., The choice of mammalian cell host and possibilities for glycosylation engineering. Curr. Opin. Biotechnol. 30 (2014), 107–112.
16. 16 Meuris, L., et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat. Biotechnol. 32 (2014), 485–489.
17. 17 Croset, A., et al. Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J. Biotechnol. 161 (2012), 336–348.
18. 18 Cervera, L., et al. Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. J. Biotechnol. 166 (2013), 152–165.
19. 19 Blondeel, E.J., et al. Tuning a MAb glycan profile in cell culture: supplementing N-acetylglucosamine to favour G0 glycans without compromising productivity and cell growth. J. Biotechnol. 214 (2015), 105–112.
20. 20 St Amand, M.M., et al. Identification of manipulated variables for a glycosylation control strategy. Biotechnol. Bioeng. 111 (2014), 1957–1970.
21. 21 Liu, B., et al. The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody. J. Biotechnol. 170 (2014), 17–27.
22. 22 Villacres, C., et al. Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO cell culture. Biotechnol. J. 10 (2015), 1051–1066.
23. 23 Aghamohseni, H., et al. Effects of nutrient levels and average culture pH on the glycosylation pattern of camelid-humanized monoclonal antibody. J. Biotechnol. 186 (2014), 98–109.
24. 24 Wang, L.X., Amin, M.N., Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions. Chem. Biol. 21 (2014), 51–66.
25. 25 Wang, P., et al. Erythropoietin derived by chemical synthesis. Science 342 (2013), 1357–1360.
26. 26 Sakamoto, I., et al. Chemical synthesis of homogeneous human glycosyl-interferon-beta that exhibits potent antitumor activity in vivo. J. Am. Chem. Soc. 134 (2012), 5428–5431.
27. 27 Aussedat, B., et al. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J. Am. Chem. Soc. 135 (2013), 13113–13120.
28. 28 Chalker, J.M., et al. A “tag-and-modify” approach to site-selective protein modification. Acc. Chem. Res. 44 (2011), 730–741.
29. 29 Spicer, C.D., Davis, B.G., Selective chemical protein modification. Nat. Commun., 5, 2014, 4740.
30. 30 Styslinger, T.J., et al. Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation. J. Am. Chem. Soc. 134 (2012), 7507–7515.
31. 31 Lukose, V., et al. Chemoenzymatic assembly of bacterial glycoconjugates for site-specific orthogonal labeling. J. Am. Chem. Soc. 137 (2015), 12446–12449.
32. 32 Pincetic, A., et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
33. 33 Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
34. 34 DiLillo, D.J., Ravetch, J.V., Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161 (2015), 1035–1045.
35. 35 Hiatt, A., et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5992–5997.
36. 36 Herter, S., et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J. Immunol. 192 (2014), 2252–2260.
37. 37 Shade, K.T., et al. A single glycan on IgE is indispensable for initiation of anaphylaxis. J. Exp. Med. 212 (2015), 457–467.
38. 38 Lin, S.C., et al. Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans. PLoS One, 8, 2013, e66719.
39. 39 Hütter, J., et al. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J. Immunol. 190 (2013), 220–230.
40. 40 Karsten, C.B., et al. Exclusive decoration of SIV Env with high-mannose type N-glycans is not compatible with mucosal transmission in rhesus macaques. J. Virol. 89 (2015), 11727–11733.
41. 41 Hudak, J.E., et al. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. 10 (2014), 69–75.
42. 42 Kawasaki, N., et al. Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation. J. Immunol. 193 (2014), 1560–1566.
43. 43 Kawasaki, N., et al. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 7826–7831.
44. 44 Macauley, M.S., et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123 (2013), 3074–3083.
45. 45 D'Alessandria, C., et al. Noninvasive in vivo imaging and biologic characterization of thyroid tumors by immunoPET targeting of galectin-3. Cancer Res. 76 (2016), 3583–3592.
46. 46 Van Woensel, M., et al. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J. Control. Release 227 (2016), 71–81.
47. 47 Lepenies, B., et al. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv. Drug Deliv. Rev. 65 (2013), 1271–1281.
48. 48 Barbuto, S., et al. Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells. Nat. Chem. Biol. 9 (2013), 250–256.
49. 49 Chappell, C.P., et al. Targeting antigens through blood dendritic cell antigen 2 on plasmacytoid dendritic cells promotes immunologic tolerance. J. Immunol. 192 (2014), 5789–5801.
50. 50 van Kooyk, Y., et al. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol. Immunol. 55 (2013), 143–145.
51. 51 Garcia-Vallejo, J.J., et al. Glycan-based DC-SIGN targeting to enhance antigen cross–presentation in anticancer vaccines. Oncoimmunology, 2, 2013, e23040.
52. 52 Fasting, C., et al. Multivalency as a chemical organization and action principle. Angew. Chem. Int. Ed. Engl. 51 (2012), 10472–10498.
53. 53 Maglinao, M., et al. A platform to screen for C-type lectin receptor-binding carbohydrates and their potential for cell-specific targeting and immune modulation. J. Control. Release 175 (2014), 36–42.
54. 54 Eriksson, M., et al. Biological evaluation of multivalent lewis X-MGL-1 interactions. ChemBioChem 15 (2014), 844–851.
55. 55 Joshi, M.D., et al. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control. Release 161 (2012), 25–37.
56. 56 Kobiyama, K., et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 3086–3091.
57. 57 Marradi, M., et al. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem. Soc. Rev. 42 (2013), 4728–4745.
58. 58 Arnaiz, B., et al. Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides. Bioconjugate Chem. 23 (2012), 814–825.
59. 59 Arosio, D., et al. Effective targeting of DC-SIGN by alpha-fucosylamide functionalized gold nanoparticles. Bioconjugate Chem. 25 (2014), 2244–2251.
60. 60 Chiodo, F., et al. Galactofuranose-coated gold nanoparticles elicit a pro-inflammatory response in human monocyte-derived dendritic cells and are recognized by DC-SIGN. ACS Chem. Biol. 9 (2014), 383–389.
61. 61 Garcia, I., et al. Glycans as biofunctional ligands for gold nanorods: stability and targeting in protein-rich media. J. Am. Chem. Soc. 137 (2015), 3686–3692.
62. 62 Kang, B., et al. Carbohydrate-based nanocarriers exhibiting specific cell targeting with minimum influence from the protein corona. Angew. Chem. Int. Ed. Engl. 54 (2015), 7436–7440.
63. 63 Farr, T.D., et al. Imaging early endothelial inflammation following stroke by core shell silica superparamagnetic glyconanoparticles that target selectin. Nano Lett. 14 (2014), 2130–2134.
64. 64 Frenz, T., et al. Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. Eur. J. Pharm. Biopharm. 95 (2015), 13–17.
65. + T-cell responses by targeting DC-SIGN on dendritic cells. J. Control. Release 160 (2012), 88–95.
66. 66 Boks, M.A., et al. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. J. Control. Release 216 (2015), 37–46.
67. 67 Boks, M.A., et al. In situ delivery of tumor antigen- and adjuvant-loaded liposomes boosts antigen-specific T-cell responses by human dermal dendritic cells. J. Invest. Dermatol. 135 (2015), 2697–2704.
68. 68 Fehres, C.M., et al. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. J. Control. Release 203 (2015), 67–76.
69. 69 Becer, C.R., The glycopolymer code: synthesis of glycopolymers and multivalent carbohydrate-lectin interactions. Macromol. Rapid Commun. 33 (2012), 742–752.
70. 70 Blattes, E., et al. Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 8795–8800.
71. 71 Gao, J., et al. Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting. Bioconjugate Chem. 24 (2013), 1332–1344.
72. 72 Garcia-Vallejo, J.J., et al. Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Int. Immunol. 25 (2013), 221–233.
73. 73 Zhang, Q., et al. Sequence-controlled multi-block glycopolymers to inhibit DC-SIGN-gp120 binding. Angew. Chem. Int. Ed. Engl. 52 (2013), 4435–4439.
74. 74 Luczkowiak, J., et al. Glycofullerenes inhibit viral infection. Biomacromolecules 14 (2013), 431–437.
75. 75 Ribeiro-Viana, R., et al. Virus-like glycodendrinanoparticles displaying quasi–equivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nat. Commun., 3, 2012, 1303.
76. 76 Sutkeviciute, I., et al. Unique DC-SIGN clustering activity of a small glycomimetic: a lesson for ligand design. ACS Chem. Biol. 9 (2014), 1377–1385.
77. 77 Varga, N., et al. A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. Biomaterials 35 (2014), 4175–4184.
78. 78 Ordanini, S., et al. Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods. Chem. Commun. 51 (2015), 3816–3819.
79. 79 Prost, L.R., et al. Noncarbohydrate glycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists. ACS Chem. Biol. 7 (2012), 1603–1608.
80. 80 Donadei, A., et al. Rational design of adjuvant for skin delivery: conjugation of synthetic beta-glucan Dectin-1 agonist to protein antigen. Mol. Pharm. 12 (2015), 1662–1672.
81. 81 Lipinski, T., et al. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J. Immunol. 190 (2013), 4116–4128.
82. 82 Zacco, E., et al. Tailored presentation of carbohydrates on a coiled coil-based scaffold for asialoglycoprotein receptor targeting. ACS Chem. Biol. 10 (2015), 2065–2072.
83. 83 Brzezicka, K.A., et al. Influence of core beta-1,2-xylosylation on glycoprotein recognition by murine C-type lectin receptors and its impact on dendritic cell targeting. ACS Chem. Biol. 11 (2016), 2347–2356.
84. 84 Garcia-Vallejo, J.J., et al. The consequences of multiple simultaneous C-type lectin-ligand interactions: DCIR alters the endo-lysosomal routing of DC-SIGN. Front. Immunol., 6, 2015, 87.
85. 85 Sancho, D., Reis e Sousa, C., Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30 (2012), 491–529.